Amgen Agrees to Acquire Tularik

Millennium Chemicals agrees to be acquired by Lyondell Chemical, and more deal news

Turalik (TLRK ) agrees to be acquired by Amgen (AMGN ) in stock deal valued at $1.3 billion, or $25 per share. Amgen already owns about 20% of Tularik, which develops oral drugs that use gene regulation to treat cancer, immune disorders, and metabolic diseases. (3/29)

To continue reading this article you must be a Bloomberg Professional Service Subscriber.